Core Viewpoint - Becton Dickinson reported a revenue of $5.89 billion for Q4 FY2025, an 8% year-over-year increase, with adjusted earnings per share of $3.96 exceeding expectations; the total annual revenue reached $21.84 billion, up 8.2% [1] Group 1: Financial Performance - Q4 FY2025 revenue was $5.89 billion, reflecting an 8% year-over-year growth [1] - Adjusted earnings per share for Q4 were $3.96, surpassing market expectations [1] - Total revenue for the fiscal year 2025 was $21.84 billion, marking an 8.2% increase compared to the previous year [1] Group 2: Institutional Perspectives - Citigroup maintained a "Buy" rating with a target price of $232 [2] - TD Cowen raised its target price to $189 while maintaining a "Hold" rating [2] - Other institutions, including Barclays, have also adjusted their target prices, focusing on the company's strategy post-business divestiture [2] Group 3: Stock Performance - The stock experienced significant volatility over the past week, with a cumulative increase of 9.87% and a fluctuation range of 15.58% [3] - On February 11, the closing price was $180.62, with a single-day increase of 5.21% [3] - On February 12, the stock closed at $178.32, reflecting a decrease of 1.27% [3] - Trading activity was robust, with a transaction volume of $1.065 billion on February 11 [3] Group 4: Recent Events - The launch of a Chinese international medical equipment and device trading platform is expected to enhance global expectations for the sector [4] - Waters Corporation completed a merger related to Becton Dickinson's business, resulting in the establishment of four new divisions focused on life sciences and diagnostics [4]

摘要 ：2025年总营收28.56亿美元，同比增长3.7%。其中，2025年诊断业务板块收入14.25亿美元，同比增长5%；生命科学业务板块收入14.31亿美元，同比 增长2%。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，瑞孚迪（Re v v it y）公布了2 0 2 5年第四季度及全年财务业绩。 2 0 2 5年总营收2 8 . 5 6亿美元，同比增长3 . 7%。 其中， 2 0 2 5年诊断业务板 块 收 入 1 4 . 2 5 亿 美 元 ， 同 比 增 长 5% ； 生 命 科 学 业 务 板 块 收 入 1 4 . 3 1 亿 美 元 ， 同 比 增 长 2% 。 对 于 2 0 2 6 财 年 ， 公 司 预 测 总 营 收 将 在 2 9 . 6 亿 至 2 9 . 9亿美元之间，有机营收增长率为2%至3%。 ▍2025年第四季度业绩 瑞孚迪（Re v v it y）公布第四季度GAAP每股收益为0 . 8 7美元，上年同期为0 . 7 8美元。2 0 2 5年Q4营收为7 . 7 2亿美元，上年同期为7 . ...

Core Viewpoint - Revvity reported a strong performance in Q3 2025, with total revenue of $699 million, reflecting a year-over-year increase. The company has raised its full-year revenue forecast to between $2.83 billion and $2.88 billion, maintaining an organic growth expectation of 2% to 4% [2][8]. Financial Performance - Q3 2025 revenue was $699 million, compared to $684 million in the same period last year, marking a growth of approximately 2.2% [4][7]. - The GAAP operating income from continuing operations for Q3 2025 was $82 million, down from $98 million in Q3 2024, resulting in an operating margin of 11.7%, down from 14.3% year-over-year [4][7]. - Adjusted earnings per share for Q3 2025 were $1.18, a decrease from $1.28 in the same quarter last year [4][7]. Segment Performance - Life Sciences segment revenue was $343 million, a slight increase of 1% from $339 million in the previous year, with organic revenue remaining flat [4][7]. - Diagnostics segment revenue reached $356 million, up 3% from $345 million year-over-year, with organic revenue growth of 2% [4][7]. Future Outlook - The company has adjusted its full-year earnings per share forecast to between $4.90 and $5.00, reflecting confidence in continued growth despite recent foreign exchange rate fluctuations [8]. - Revvity's CEO highlighted the positive impact of key innovations and strategic partnerships, indicating a strong execution capability that is expected to drive success in 2026 and beyond [4]. Shareholder Returns - The board has approved a new two-year stock repurchase program totaling $1 billion, replacing the remaining portion of the previous buyback plan announced in October 2024 [4].

Core Insights - Thermo Fisher Scientific plans to sell part of its diagnostics business for $4 billion [1] Company Summary - The sale is part of Thermo Fisher's strategy to streamline operations and focus on core areas of growth [1] - The divestiture is expected to enhance the company's financial flexibility and allow for reinvestment in higher-growth segments [1] Industry Context - The diagnostics market is experiencing significant changes, with companies reassessing their portfolios to adapt to evolving healthcare demands [1] - This move reflects a broader trend in the industry where firms are divesting non-core assets to concentrate on more profitable areas [1]